
Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint
Immunic’s oral multiple sclerosis drug failed to significantly slow the loss of brain volume in patients with a progressing form of the neurodegenerative disorder during a Phase II clinical trial. But according to CEO Daniel Vitt, it’s no big deal. “Nobody …